Eckert & Ziegler stock: NuWays sets EUR 21.50 target, slightly higher pre-market
Published on 10/20/2026 at 08:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNuWays updates its research view
- In a research update dated October 19, 2026, NuWays rated the shares Buy and assigned a EUR 21.50 target.
- Germany's DAX is the benchmark for the Xetra-listed shares on October 20, 2026.
- Eckert & Ziegler stock trades pre-market at EUR 12.96 at 8:14 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.31 percent above the Xetra close of October 19, 2026.
NuWays assigned Eckert & Ziegler a Buy rating and a EUR 21.50 target in a research update dated October 19, 2026, distributed through EQS News and reported by EQS News via BörsenNEWS.de. Eckert & Ziegler stock trades pre-market at EUR 12.96 at 8:14 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.31 percent above the Xetra close of October 19, 2026 (EUR 12.92).
NuWays updates its research view
The research cited recovering profitability at the Isotope Products segment, rising lutetium-177 sales and license income as potential contributors to second-half performance. NuWays projected third-quarter revenue of EUR 78.80 million and adjusted EBIT of EUR 18.20 million, according to the EQS News via BörsenNEWS.de.
Ahead of the Xetra open
The stock is EUR 0.04 above the Xetra close. The bid is EUR 12.82 and the ask is EUR 13.10, a spread of 2.16 percent, indicating a wide pre-market spread. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Eckert & Ziegler stock.
How the group makes its money
Eckert & Ziegler makes isotopic components for medical, scientific and measurement applications across its Medical and Isotope Products segments, as described on its investor-relations website. Germany's DAX is the benchmark for the Xetra-listed shares on October 20, 2026. Market context: Market report DAX.
